NCT04425707.

Study name	Ivermectin In treatment of COVID 19 patients
Methods	Trial design: open‐label RCT with 3 parallel arms, only 2 arms relevant; the third arm investigates ivermectin without standard of care compared to standard of care which then equals an active comparator Type of record: trial register entry Sample size: 100 Setting: inpatient Country: Egypt Language: English Number of centres: NR Study purpose (treatment, prevention): treatment Trial registration number: NCT04425707 Date of registration: 11 June 2020
Participants	Inclusion criteria Asymptomatic mild cases and moderate cases proven to be infected by COVID‐19 by viral RNA swap Age ≥ 18 years Exclusion criteria: Contraindications for the drug: hypersensitivity Any medications with possible drug interactions Severe cases Any malignant condition Pregnant females Breastfeeding women Receiving following medications: erdafitinib, lasmiditan, quinidine due to potential severe drug interaction
Interventions	Details of intervention of relevant arms Type and dose: ivermectin, dosing and frequency NR Route of administration: oral Treatment details of control group No treatment except standard of care Concomitant therapy: standard of care (no details provided) administered in both study arms
Outcomes	Primary study outcome NR Relevant review outcomes planned None Additional study outcomes Rate of viral clearance in comparison to other treatment protocols
Starting date	9 June 2020
Contact information	Dr Ehab Kamal General Director of Fever Hospitals Ministry of Health and Population Cairo Egypt
Notes	Recruitment status: recruiting Prospective completion date: 1 September 2020 Date last update posted: 11 June 2020 Sponsor/funding: Ministry of Health and Population, Egypt